Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Table of Contents

Page standards status: Informative
.. 0 Table of Contents
... 1 Introduction
... 2 Evidence Profiles
... 3 EvidenceVariable Profiles
... 4 Group Profiles
... 5 Citation Profiles
... 6 ArtifactAssessment Profiles
... 7 Composition Profiles
... 8 Other Profiles
... 9 Profiles
... 10 Extensions
... 11 Terminologies
... 12 Examples
... 13 Downloads
... 14 Artifacts Summary
.... 14.1 AbsenceOfExposureDefinition
.... 14.2 Adaptation
.... 14.3 BaselineMeasureEvidence
.... 14.4 BaselineMeasureReport
.... 14.5 BaselineVariablesList
.... 14.6 BookCitation
.... 14.7 BookPartCitation
.... 14.8 CertaintyOfEvidence
.... 14.9 Classification
.... 14.10 CohortDefinition
.... 14.11 Comment
.... 14.12 ComparativeBaselineMeasureEvidence
.... 14.13 ComparativeEvidence
.... 14.14 ComparativeEvidenceReport
.... 14.15 ComparativeEvidenceReportExpanded
.... 14.16 ComparativeEvidenceReportSubject
.... 14.17 ComparativeEvidenceSynthesisReport
.... 14.18 ComparativeParticipantFlowEvidence
.... 14.19 ComparatorGroup
.... 14.20 ComparatorOnlyEvidence
.... 14.21 Comparison
.... 14.22 CompositeRating
.... 14.23 ConceptualCohortDefinition
.... 14.24 ConceptualComparatorDefinition
.... 14.25 ConceptualExposureDefinition
.... 14.26 DatabaseCitation
.... 14.27 DatabaseEntryCitation
.... 14.28 DatasetCitation
.... 14.29 DateAsRating
.... 14.30 DichotomousIntendedOutcome
.... 14.31 EndpointAnalysisPlan
.... 14.32 EvidenceAssessment
.... 14.33 EvidenceList
.... 14.34 EvidenceReport
.... 14.35 EvidenceReportPackage
.... 14.36 EvidenceReportSubject
.... 14.37 EvidenceSynthesisEvidence
.... 14.38 ExposureGroup
.... 14.39 GroupAssignment
.... 14.40 GroupR6
.... 14.41 Guideline
.... 14.42 InterventionOnlyEvidence
.... 14.43 JournalArticleCitation
.... 14.44 M11Report
.... 14.45 MetaanalysisEligibilityCriteria
.... 14.46 MetaanalysisOutcomeDefinition
.... 14.47 MetaanalysisStudyGroup
.... 14.48 NetEffectContribution
.... 14.49 NetEffectContributionList
.... 14.50 NetEffectContributions
.... 14.51 NetEffectEstimate
.... 14.52 NonComparativeEvidence
.... 14.53 OutcomeDefinition
.... 14.54 OutcomeImportance
.... 14.55 OutcomeList
.... 14.56 OutcomeMeasureReport
.... 14.57 OutcomeVariablesList
.... 14.58 ParticipantFlowEvidence
.... 14.59 ParticipantFlowEvidenceVariable
.... 14.60 ParticipantFlowReasonEvidenceVariable
.... 14.61 ParticipantFlowReport
.... 14.62 ParticipantFlowVariablesList
.... 14.63 PreprintCitation
.... 14.64 Rating
.... 14.65 Recommendation
.... 14.66 RecommendationAction
.... 14.67 RecommendationEligibilityCriteria
.... 14.68 RecommendationJustification
.... 14.69 RecommendationPlan
.... 14.70 RecommendationRating
.... 14.71 ResearchStudyDataDictionary
.... 14.72 ResearchStudySupport
.... 14.73 RiskOfBias
.... 14.74 SearchResults
.... 14.75 SearchStrategy
.... 14.76 SingleStudyEvidence
.... 14.77 SoaPlanDefinition
.... 14.78 SoftwareCitation
.... 14.79 StatisticModel
.... 14.80 StudyComponent
.... 14.81 StudyDesign
.... 14.82 StudyEligibilityCriteria
.... 14.83 StudyGroup
.... 14.84 StudyRegistryRecord
.... 14.85 SummaryOfFindings
.... 14.86 SummaryOfNetEffect
.... 14.87 SystematicReview
.... 14.88 SystematicReviewEligibilityCriteria
.... 14.89 SystematicReviewExcludedStudies
.... 14.90 SystematicReviewIncludedStudies
.... 14.91 VariableDefinition
.... 14.92 WebPageCitation
.... 14.93 ArtifactAssessmentCompared
.... 14.94 ArtifactAssessmentDateAsRating
.... 14.95 ArtifactPublicationStatus
.... 14.96 ArtifactRecorder
.... 14.97 CharacteristicTiming
.... 14.98 CiteAs
.... 14.99 EvidenceVariableHandlingDetail
.... 14.100 GuidelineRegistration
.... 14.101 NumberAnalyzed
.... 14.102 RelatesTo
.... 14.103 RelatesToClassifier
.... 14.104 RelatesToWithQuotation
.... 14.105 RelativeOutcomeImportance
.... 14.106 ResearchStudyExcludedStudy
.... 14.107 ResearchStudyIncludedStudy
.... 14.108 ResearchStudyIsLowInterventionTrial
.... 14.109 ResearchStudyIsRareDisease
.... 14.110 ResearchStudyNumberOfStudiesIdentified
.... 14.111 ResearchStudyNumberOfStudiesIncluded
.... 14.112 ResearchStudySaeReportingMethod
.... 14.113 ResearchStudySearchStrategy
.... 14.114 ResearchStudySponsorConfidentialityStatement
.... 14.115 ResearchStudyStudyAmendment
.... 14.116 ResearchStudySystematicReviewEligibilityCriteria
.... 14.117 StatisticModelExpression
.... 14.118 StatisticModelIncludeIf
.... 14.119 Desirability Codes Value Set
.... 14.120 EBMonFHIR Profile Name Value Set
.... 14.121 Evidence Rating System Classifier Codes Value Set
.... 14.122 Recommendation Justification Classifier Codes Value Set
.... 14.123 Research Study Document Types Value Set
.... 14.124 ResearchStudy Classifier Value Set
.... 14.125 Search Strategy Characteristic Value Set
.... 14.126 Desirability Code System
.... 14.127 EBMonFHIR Profile Name Code System
.... 14.128 Evidence Rating System Classifier Code System
.... 14.129 Research Study Document Types Code System
.... 14.130 Search Strategy Characteristic Code System
.... 14.131 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
.... 14.132 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.133 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
.... 14.134 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
.... 14.135 15855602 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.
.... 14.136 179899
.... 14.137 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers.
.... 14.138 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
.... 14.139 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
.... 14.140 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
.... 14.141 19967827 Wonder woman was Argentine and her real name was Evita.
.... 14.142 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
.... 14.143 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
.... 14.144 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
.... 14.145 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
.... 14.146 23589542 Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
.... 14.147 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
.... 14.148 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
.... 14.149 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
.... 14.150 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
.... 14.151 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
.... 14.152 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
.... 14.153 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
.... 14.154 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.
.... 14.155 26681725 Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
.... 14.156 26859072 Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns.
.... 14.157 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.
.... 14.158 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
.... 14.159 27979893 6. Glycemic Targets.
.... 14.160 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego.
.... 14.161 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character.
.... 14.162 29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image.
.... 14.163 29357271 Using Hawkeye from the Avengers to communicate on the eye.
.... 14.164 29694275 A regressive formula of perversity: Wertham and the women of comics.
.... 14.165 29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics.
.... 14.166 30467172 Finding my inner Wonder Woman.
.... 14.167 30545967 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 14.168 34871555 What Can Wonder Woman Teach Radiologists?
.... 14.169 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
.... 14.170 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst.
.... 14.171 367832
.... 14.172 367833
.... 14.173 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
.... 14.174 38584159 Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial.
.... 14.175 6907780 Career guide: to change what needs changing...doesn't take Wonder Woman.
.... 14.176 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus
.... 14.177 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 14.178 ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.179 Add-on Amlodipine at 6 weeks
.... 14.180 Adults with diabetes mellitus type 2
.... 14.181 Adults with type 2 diabetes and CVD and CKD
.... 14.182 Adults with type 2 diabetes and established CVD (but no CKD)
.... 14.183 Adverse event free and hypertension control
.... 14.184 Adverse event free and hypertension control at 12 weeks
.... 14.185 Adverse Events Report for NCT03421379
.... 14.186 Adverse Events Report for NCT03640312
.... 14.187 Age
.... 14.188 Age with comparator
.... 14.189 Age with intervention
.... 14.190 Aircraft Type
.... 14.191 Aircraft Type with comparator
.... 14.192 Aircraft Type with intervention
.... 14.193 Altitude
.... 14.194 Altitude comparing intervention vs. comparator
.... 14.195 Altitude for enrolled group
.... 14.196 Altitude for screened group
.... 14.197 Altitude with comparator
.... 14.198 Altitude with intervention
.... 14.199 Analyzed Group in PARACHUTE Trial
.... 14.200 Anticoagulation for COVID-19 Combined RCTs in NEJM
.... 14.201 Baseline Characteristics Report for NCT03421379
.... 14.202 Baseline Characteristics Report for NCT03640312
.... 14.203 Baseline Characteristics Report for QUARTET Trial
.... 14.204 Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.205 Baseline Measures List for PARACHUTE Trial
.... 14.206 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group
.... 14.207 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group
.... 14.208 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group
.... 14.209 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group
.... 14.210 BaselineVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.211 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
.... 14.212 BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.213 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.214 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation
.... 14.215 Candesartan 8 mg once daily
.... 14.216 Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.217 Change in Mean Diastolic Blood Pressure (NCT03640312)
.... 14.218 Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.219 Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.220 Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.221 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 14.222 Change in Mean Systolic Blood Pressure (NCT03640312)
.... 14.223 Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312
.... 14.224 Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.225 Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.226 Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.227 Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.228 Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.229 CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.230 Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.231 Citation for EBMonFHIR Implementation Guide
.... 14.232 Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.233 Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19
.... 14.234 Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.235 Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z
.... 14.236 Comparative Evidence Report for QUARTET USA Trial
.... 14.237 ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.238 ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.239 ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 14.240 ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)
.... 14.241 ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 14.242 ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 14.243 ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 14.244 ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 14.245 ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 14.246 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014
.... 14.247 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015
.... 14.248 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016
.... 14.249 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015
.... 14.250 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008
.... 14.251 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014
.... 14.252 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013
.... 14.253 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015
.... 14.254 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013
.... 14.255 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial
.... 14.256 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial
.... 14.257 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014
.... 14.258 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial
.... 14.259 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial
.... 14.260 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014
.... 14.261 ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.262 ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.263 ComparativeEvidenceReportSubject: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.264 ComparativeEvidenceSynthesisReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.265 ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial
.... 14.266 ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 14.267 ComparatorDefinition: Obese patients ≥ 18 years old without bariatric surgery
.... 14.268 ComparatorDefinition: Standard care
.... 14.269 ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 14.270 ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.271 ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis
.... 14.272 ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study
.... 14.273 ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.274 ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.275 ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.276 Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.277 Composite Rating of FOI 153881 for Project FOI 112280
.... 14.278 Computable_Publishing_LLC
.... 14.279 ConceptualCohortDefinition: At least 2 risk factors for stroke
.... 14.280 ConceptualCohortDefinition: BMI 27.5-32.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.281 ConceptualCohortDefinition: BMI 30-34.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.282 ConceptualCohortDefinition: BMI 32.5-37.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.283 ConceptualCohortDefinition: BMI 35-39.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery
.... 14.284 ConceptualCohortDefinition: BMI criteria for ADA surgery recommendation
.... 14.285 ConceptualCohortDefinition: BMI ≥ 35 and at least 1 obesity-related comorbidity
.... 14.286 ConceptualCohortDefinition: BMI ≥ 37.5 kg/m2 in Asian Americans
.... 14.287 ConceptualCohortDefinition: Estimated glomerular filtration rate 45-59
.... 14.288 ConceptualCohortDefinition: Heart failure based on Phenotypes
.... 14.289 ConceptualCohortDefinition: Lower BMI criteria for ADA surgery consideration
.... 14.290 ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria
.... 14.291 ConceptualCohortDefinition: Nonfatal myocardial infarction
.... 14.292 ConceptualCohortDefinition: Nonfatal stroke
.... 14.293 ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter
.... 14.294 ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter with Ranges
.... 14.295 ConceptualCohortDefinition: Proxy criteria for surgical candidates
.... 14.296 ConceptualCohortDefinition: Severe obesity
.... 14.297 ConceptualCohortDefinition: T1DM or T2DM
.... 14.298 ConceptualCohortDefinition: T1DM-specific criteria
.... 14.299 ConceptualCohortDefinition: T2DM-specific criteria
.... 14.300 ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years
.... 14.301 ConceptualCohortDefinition_Cardiovascular_event
.... 14.302 ConceptualComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.303 ConceptualComparatorDefinition: Usual-care pharmacologic thromboprophylaxis
.... 14.304 ConceptualExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.305 ConceptualExposureDefinition: Therapeutic-dose anticoagulation with heparin
.... 14.306 COVID_19PneumoniaHospitalizedAdult
.... 14.307 Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.308 CTIS2024-516402-32-00 Eligibility Criteria
.... 14.309 CTIS2024-516402-32-00 Primary Outcome 1
.... 14.310 CTIS2024-516402-32-00 Secondary Outcome 1
.... 14.311 CTIS2024-516402-32-00 Secondary Outcome 2
.... 14.312 CTIS2024-516402-32-00 Secondary Outcome 3
.... 14.313 CTIS2024-516402-32-00 Secondary Outcome 4
.... 14.314 CTIS2024-516402-32-00 Secondary Outcome 5
.... 14.315 CTIS2024-516402-32-00 Secondary Outcome 6
.... 14.316 CTIS2024-516402-32-00 Secondary Outcome 7
.... 14.317 CTIS2024-516402-32-00 Secondary Outcome 8
.... 14.318 DatabaseCitation: Citation for FEvIR Platform
.... 14.319 DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.320 DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes
.... 14.321 DateOfFirstPublication Classification of FOI 153881 by Rachel Couban
.... 14.322 Death or Major Traumatic Injury 30 days after Impact comparing intervention vs. comparator
.... 14.323 Death or Major Traumatic Injury 30 days after Impact with comparator
.... 14.324 Death or Major Traumatic Injury 30 days after Impact with intervention
.... 14.325 Death or Major Traumatic Injury on Impact comparing intervention vs. comparator
.... 14.326 declined randomization in PARACHUTE Study
.... 14.327 deemed unsuitable by investigator in PARACHUTE Trial
.... 14.328 Delany-Moretlwe 2022 clinical trial
.... 14.329 Diabetes treatment medication
.... 14.330 Diastolic blood pressure at 12 weeks
.... 14.331 DichotomousIntendedOutcome: Death or Major Traumatic Injury within 30 days
.... 14.332 Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU)
.... 14.333 Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension
.... 14.334 Efficacy of Corticosteroids in COVID-19 Patients: A Systematic Review and Meta-Analysis
.... 14.335 Eligibility criteria for NMA_Diabetes
.... 14.336 Eligibility Criteria for QUARTET USA Trial
.... 14.337 Enrolled Group for QUARTET USA Trial
.... 14.338 Enrolled Group PARACHUTE Trial
.... 14.339 Ethnic Group
.... 14.340 Ethnic Group with comparator
.... 14.341 Ethnic Group with intervention
.... 14.342 Evidence Based Medicine on FHIR Implementation Guide Code System
.... 14.343 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.344 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.345 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Control Group
.... 14.346 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Quadpill group
.... 14.347 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.348 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.349 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Control Group
.... 14.350 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.351 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.352 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.353 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 14.354 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.355 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.356 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.357 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Control Group
.... 14.358 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.359 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.360 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.361 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Control Group
.... 14.362 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.363 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.364 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan
.... 14.365 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Control Group
.... 14.366 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group
.... 14.367 Evidence List: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY)
.... 14.368 EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.369 EvidenceReportSectionCode Value Set
.... 14.370 EvidenceReportSubject: Clinical Outcomes for Effects of Bariatric Surgery
.... 14.371 EvidenceVariable Handling Extension Value Set
.... 14.372 EvidenceVariable: case_id
.... 14.373 EvidenceVariable: Patient id
.... 14.374 EvidenceVariable: Time of measurement
.... 14.375 Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.376 Excluded from PARACHUTE Study
.... 14.377 ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort
.... 14.378 ExposureVariable: Age (as continuous variable)
.... 14.379 ExposureVariable: Body Mass Index (as continuous variable)
.... 14.380 ExposureVariable: pht013093.v1.p1 Age at diagnosis
.... 14.381 ExposureVariable: pht013093.v1.p1 RACE
.... 14.382 ExposureVariable: pht013093.v1.p1 SEX
.... 14.383 ExposureVariable: pht013093.v1.p1 SUBJECT_ID
.... 14.384 ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE
.... 14.385 ExposureVariable: pht013094.v1.p1 BODY_SITE
.... 14.386 ExposureVariable: pht013094.v1.p1 IS_TUMOR
.... 14.387 ExposureVariable: pht013094.v1.p1 SAMPLE_ID
.... 14.388 ExposureVariable: pht013094.v1.p1 SAMPLE_USE
.... 14.389 ExposureVariable: pht013094.v1.p1 Source_Type
.... 14.390 Family History of Parachute Use
.... 14.391 Family History of Parachute Use with comparator
.... 14.392 Family History of Parachute Use with intervention
.... 14.393 Frequent Flier
.... 14.394 Frequent Flier with comparator
.... 14.395 Frequent Flier with intervention
.... 14.396 GLP-1 RA Group in Adults with type 2 diabetes
.... 14.397 GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk
.... 14.398 Glucagon Hydrochloride Solution (Active Comparator)
.... 14.399 Glucagon Nasal Powder (Experimental)
.... 14.400 Group Randomized to Comparator (empty backpack) in PARACHUTE Trial
.... 14.401 Group Randomized to Intervention Group (parachute) in PARACHUTE Trial
.... 14.402 GroupAssignment: Bariatric Surgery vs. no bariatric surgery
.... 14.403 GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.404 GroupAssignment: ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort vs. ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 14.405 GroupAssignment: GLP-1 RA vs. Standard care
.... 14.406 GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo
.... 14.407 GroupAssignment: Jumping from aircraft with parachute vs. Jumping from aircraft with empty backpack
.... 14.408 GroupAssignment: Non Participants vs. Enrolled Participants
.... 14.409 GroupAssignment: Quadpill vs. Candesartan
.... 14.410 GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment
.... 14.411 GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone
.... 14.412 GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment
.... 14.413 GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
.... 14.414 GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis
.... 14.415 Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.416 Health Survey Score Total
.... 14.417 Health Survey Score Total comparing intervention vs. comparator
.... 14.418 Health Survey Score Total with comparator
.... 14.419 Health Survey Score Total with intervention
.... 14.420 Health Survey Score-Mental Health Subscore
.... 14.421 Health Survey Score-Mental Health Subscore comparing intervention vs. comparator
.... 14.422 Health Survey Score-Mental Health Subscore with comparator
.... 14.423 Health Survey Score-Mental Health Subscore with intervention
.... 14.424 Health Survey Score-Physical Health Subscore
.... 14.425 Health Survey Score-Physical Health Subscore comparing intervention vs. comparator
.... 14.426 Health Survey Score-Physical Health Subscore with comparator
.... 14.427 Health Survey Score-Physical Health Subscore with intervention
.... 14.428 Health-related Quality of Life (NCT03640312)
.... 14.429 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312)
.... 14.430 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312
.... 14.431 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 14.432 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312)
.... 14.433 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312
.... 14.434 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312
.... 14.435 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.436 Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.437 Height
.... 14.438 Height with comparator
.... 14.439 Height with intervention
.... 14.440 High Blood Pressure Medication Value Set
.... 14.441 History of Acrophobia
.... 14.442 History of Acrophobia with comparator
.... 14.443 History of Acrophobia with intervention
.... 14.444 History of Broken Bones
.... 14.445 History of Broken Bones with comparator
.... 14.446 History of Broken Bones with intervention
.... 14.447 History of Parachute Use
.... 14.448 History of Parachute Use with comparator
.... 14.449 History of Parachute Use with intervention
.... 14.450 Hypertension Control at 12 weeks
.... 14.451 ICD-10-GM Terminale Codes
.... 14.452 Injury Severity Score 30 days after Impact comparing intervention vs. comparator
.... 14.453 Injury Severity Score 30 days after Impact with comparator
.... 14.454 Injury Severity Score 30 days after Impact with intervention
.... 14.455 Injury Severity Score on Impact comparing intervention vs. comparator
.... 14.456 Injury Severity Score on Impact with comparator
.... 14.457 Injury Severity Score on Impact with intervention
.... 14.458 International vs Domestic Flight
.... 14.459 International vs Domestic Flight with comparator
.... 14.460 International vs Domestic Flight with intervention
.... 14.461 InterventionDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists
.... 14.462 InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
.... 14.463 InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.464 InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.465 InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.466 InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.467 Investigator
.... 14.468 Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA
.... 14.469 IV remdesivir 200 mg then 100 mg/day for 9 days
.... 14.470 Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.471 JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.472 JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.473 Jumping from aircraft with empty backpack
.... 14.474 Jumping from aircraft with parachute
.... 14.475 Justification for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.476 Justification for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.477 M11 IGBJ Protocol Example Eligibility Criteria
.... 14.478 M11 IGBJ Protocol Example for EBMonFHIR IG
.... 14.479 M11 Report Template Instructions
.... 14.480 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.481 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.482 MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.483 MAGIC-derived ComparatorOnlyEvidence: Body weight in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.484 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.485 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.486 MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.487 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.488 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.489 MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.490 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.491 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.492 MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.493 MAGIC-derived ComparatorOnlyEvidence: Heart failure in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.494 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.495 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.496 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.497 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.498 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.499 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.500 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes
.... 14.501 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.502 MAGIC-derived Evidence: All-cause mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.503 MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.504 MAGIC-derived Evidence: Body weight with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.505 MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.506 MAGIC-derived Evidence: Cardiovascular mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.507 MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.508 MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.509 MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.510 MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.511 MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.512 MAGIC-derived Evidence: Health-related quality of life with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.513 MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.514 MAGIC-derived Evidence: Heart failure with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.515 MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.516 MAGIC-derived Evidence: Nonfatal myocardial infarction with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.517 MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.518 MAGIC-derived Evidence: Nonfatal stroke with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.519 MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.520 MAGIC-derived Evidence: Serious hyperglycaemia with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.521 MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.522 MAGIC-derived Evidence: Severe gastrointestinal events with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.523 MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.524 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.525 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.526 MAGIC-derived InterventionOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.527 MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.528 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.529 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.530 MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.531 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.532 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.533 MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.534 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.535 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.536 MAGIC-derived InterventionOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.537 MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.538 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.539 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.540 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.541 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.542 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.543 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.544 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk
.... 14.545 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.546 Mean Change in Blood Urea Nitrogen (NCT03640312)
.... 14.547 Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312
.... 14.548 Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.549 Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.550 Mean Change in Serum Creatinine (NCT03640312)
.... 14.551 Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312
.... 14.552 Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.553 Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.554 Mean Change in Serum Potassium (NCT03640312)
.... 14.555 Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312
.... 14.556 Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.557 Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.558 Mean Change in Serum Sodium (NCT03640312)
.... 14.559 Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312
.... 14.560 Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.561 Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.562 Mean Diastolic Blood Pressure (NCT03640312)
.... 14.563 Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.564 Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.565 Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.566 Mean Systolic Blood Pressure (NCT03640312)
.... 14.567 Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312
.... 14.568 Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.569 Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.570 Median Age of Parachute Intervention Group
.... 14.571 Medication Adherence (NCT03640312)
.... 14.572 Medication Adherence at 12 weeks
.... 14.573 Medication Adherence at 12 weeks for Candesartan in NCT03640312
.... 14.574 Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.575 Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.576 MetaanalysisEligibilityCriteria: Mean difference in HbA1c effect of bariatric surgery in type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 14.577 MetaanalysisOutcomeDefinition: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 14.578 MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs
.... 14.579 MetaanalysisStudyGroup: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.580 Mortality at 14 days
.... 14.581 NCT03421379 Eligibility Criteria
.... 14.582 NCT03640312 Eligibility Criteria
.... 14.583 NetEffectContribution: Additional GI surgical procedure for Example for GIN 2022
.... 14.584 NetEffectContribution: All-cause mortality for Example for GIN 2022
.... 14.585 NetEffectContribution: New onset depression for Example for GIN 2022
.... 14.586 NetEffectContribution: Nonfatal myocardial infarction or stroke for Example for GIN 2022
.... 14.587 NetEffectContribution: Remission of diabetes for Example for GIN 2022
.... 14.588 NetEffectContribution: Treatment with opioids for Example for GIN 2022
.... 14.589 NetEffectContributionList: Bariatric Surgery Example for GIN 2022
.... 14.590 NetEffectContributions: Bariatric Surgery Example for GIN 2022
.... 14.591 NetEffectEstimate: Bariatric Surgery Example for GIN 2022
.... 14.592 NHANES LBDGLUSI Variable Definition Cohort Definition
.... 14.593 NHANES LBDGLUSI: Fasting Glucose (mmol/L)
.... 14.594 NHANES LBXGLU Variable Definition Cohort Definition
.... 14.595 NHANES LBXGLU: Fasting Glucose (mg/dL)
.... 14.596 NHANES Plasma Fasting Glucose (GLU_J) Data Dictionary
.... 14.597 NHANES SEQN Respondent Sequence Number
.... 14.598 NHANES WTSAF2YR Variable Definition Cohort Definition
.... 14.599 NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight
.... 14.600 Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities
.... 14.601 NT-proBNP Study Data Dictionary
.... 14.602 Number of Patients Requiring Step up Treatment (NCT03640312)
.... 14.603 Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312
.... 14.604 Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312
.... 14.605 Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.606 Organ support-free days
.... 14.607 Outcome Importance Rating 100 of All-cause mortality
.... 14.608 Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke
.... 14.609 Outcome Importance Rating 5 of New onset depression
.... 14.610 Outcome Importance Rating 5 of Remission of diabetes
.... 14.611 Outcome Importance Rating 5 of Treatment with opioids
.... 14.612 Outcome Importance Rating 8 of Additional GI surgical procedure
.... 14.613 Outcome Measure List for QUARTET USA Trial
.... 14.614 Outcome Measure Report for QUARTET USA Trial
.... 14.615 Outcome Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.616 Outcome Measures Report for NCT03421379
.... 14.617 Outcome Measures Report for NCT03640312
.... 14.618 Outcome Variables List for PARACHUTE Trial
.... 14.619 Outcome: Death or Major Traumatic Injury 30 days after Impact
.... 14.620 Outcome: Death or Major Traumatic Injury on Impact
.... 14.621 Outcome: Injury Severity Score 30 days after Impact
.... 14.622 Outcome: Injury Severity Score on Impact
.... 14.623 OutcomeDefinition: Injury Severity Score on Impact
.... 14.624 OutcomeDefinition: All-cause mortality
.... 14.625 OutcomeDefinition: All-cause mortality
.... 14.626 OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control
.... 14.627 OutcomeDefinition: Body weight
.... 14.628 OutcomeDefinition: Body weight
.... 14.629 OutcomeDefinition: Cardiovascular mortality
.... 14.630 OutcomeDefinition: Cardiovascular mortality
.... 14.631 OutcomeDefinition: Diabetes in remission
.... 14.632 OutcomeDefinition: Diabetic ketoacidosis
.... 14.633 OutcomeDefinition: End-stage kidney disease
.... 14.634 OutcomeDefinition: End-stage kidney disease
.... 14.635 OutcomeDefinition: Genital infection
.... 14.636 OutcomeDefinition: HbA1c at 12 months
.... 14.637 OutcomeDefinition: HbA1c at 24 months
.... 14.638 OutcomeDefinition: HbA1c at 36 months
.... 14.639 OutcomeDefinition: HbA1c at 6 months
.... 14.640 OutcomeDefinition: HbA1c at 60 months
.... 14.641 OutcomeDefinition: Health-related quality of life
.... 14.642 OutcomeDefinition: Health-related quality of life
.... 14.643 OutcomeDefinition: Heart failure
.... 14.644 OutcomeDefinition: Heart failure
.... 14.645 OutcomeDefinition: Mortality at 14 days
.... 14.646 OutcomeDefinition: New onset depression
.... 14.647 OutcomeDefinition: Nonfatal myocardial infarction
.... 14.648 OutcomeDefinition: Nonfatal myocardial infarction
.... 14.649 OutcomeDefinition: Nonfatal myocardial infarction or stroke
.... 14.650 OutcomeDefinition: Nonfatal stroke
.... 14.651 OutcomeDefinition: Nonfatal stroke
.... 14.652 OutcomeDefinition: Serious hyperglycaemia
.... 14.653 OutcomeDefinition: Serious hyperglycaemia
.... 14.654 OutcomeDefinition: Severe gastrointestinal events
.... 14.655 OutcomeDefinition: Severe gastrointestinal events
.... 14.656 OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery
.... 14.657 OutcomeMeasureReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.658 OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years
.... 14.659 OutcomeVariable: HbA1c at 12 months
.... 14.660 OutcomeVariable: HbA1c at 24 months
.... 14.661 OutcomeVariable: HbA1c at 36 months
.... 14.662 OutcomeVariable: HbA1c at 6 months
.... 14.663 OutcomeVariable: HbA1c at 60 months
.... 14.664 OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 14.665 OutcomeVariable: New onset depression
.... 14.666 OutcomeVariable: Nonfatal myocardial infarction or stroke
.... 14.667 OutcomeVariable: Remission of diabetes
.... 14.668 OutcomeVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.669 OutcomeVariable_Additional_GI_surgical_procedure
.... 14.670 OutcomeVariable_All_cause_mortality
.... 14.671 OutcomeVariable_Treatment_with_opioids
.... 14.672 PARACHUTE Trial baseline characteristics
.... 14.673 PARACHUTE Trial non participants
.... 14.674 PARACHUTE trial participant flow report
.... 14.675 PARACHUTE Trial Participants
.... 14.676 PARACHUTE Trial Participants assigned an empty backpack
.... 14.677 PARACHUTE trial participants assigned parachute
.... 14.678 PARACHUTE Trial Participants available for randomization
.... 14.679 PARACHUTE Trial Participants deemed unsuitable by investigator
.... 14.680 PARACHUTE Trial Participants randomized into groups
.... 14.681 PARACHUTE Trial Participants randomized into groups for screened group
.... 14.682 PARACHUTE Trial Participants randomized into groups with comparator
.... 14.683 PARACHUTE Trial Participants randomized into groups with intervention
.... 14.684 PARACHUTE Trial Participants that completed 30 day follow up
.... 14.685 PARACHUTE Trial Participants that completed 30 day follow up with comparator
.... 14.686 PARACHUTE Trial Participants that completed 30 day follow up with intervention
.... 14.687 PARACHUTE Trial Participants that completed jump and 5 minute follow-up
.... 14.688 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with comparator
.... 14.689 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with intervention
.... 14.690 PARACHUTE Trial Participants that declined randomization
.... 14.691 PARACHUTE Trial Participants with no contact at 30 days
.... 14.692 PARACHUTE Trial Participants with no contact at 30 days with comparator
.... 14.693 PARACHUTE Trial Participants with no contact at 30 days with intervention
.... 14.694 PARACHUTE Trial Results
.... 14.695 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.
.... 14.696 Parachute vs Empty Backpack in PARACHUTE Trial
.... 14.697 Participant Flow Report for NCT03421379
.... 14.698 Participant Flow Report for NCT03640312
.... 14.699 Participant Flow Report for QUARTET USA Trial
.... 14.700 Participant Flow Variables List for PARACHUTE Trial
.... 14.701 ParticipantFlow: 2018 Norwegian Cohort Included in Analysis
.... 14.702 ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis
.... 14.703 ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis
.... 14.704 ParticipantFlowEvidence: 2018 Norwegian Cohort Excluded from Analysis
.... 14.705 ParticipantFlowMeasure: Dropout due to stopping intervention
.... 14.706 ParticipantFlowMeasure: Exclusion from analysis
.... 14.707 ParticipantFlowMeasure: Inclusion in analysis
.... 14.708 Participants Excluded from PARACHUTE Study
.... 14.709 Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill
.... 14.710 Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill
.... 14.711 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 14.712 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 14.713 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 14.714 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379)
.... 14.715 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 14.716 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 14.717 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration Statistical Analysis for Glucagon Nasal Powder vs Glucagon Hydrochloride Solution in NCT03421379
.... 14.718 Percentage of Participants With Potentially Related Adverse Events (NCT03640312)
.... 14.719 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312
.... 14.720 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.721 Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.722 Percentage of Participants With Serious Adverse Events (SAEs) (NCT03640312)
.... 14.723 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312
.... 14.724 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.725 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.726 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379)
.... 14.727 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 14.728 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 14.729 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 14.730 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 14.731 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 14.732 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 14.733 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 14.734 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 14.735 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379)
.... 14.736 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379
.... 14.737 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379
.... 14.738 Placebo
.... 14.739 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.740 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.741 PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint
.... 14.742 Proportion of Patients With Adverse Event Free Hypertension Control (NCT03640312)
.... 14.743 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312
.... 14.744 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.745 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.746 Proportion of Patients With Hypertension Control (NCT03640312)
.... 14.747 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312)
.... 14.748 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312
.... 14.749 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312
.... 14.750 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312)
.... 14.751 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312
.... 14.752 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312
.... 14.753 Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.754 Quadpill once daily
.... 14.755 QUARTET USA Trial Control Group
.... 14.756 QUARTET USA Trial Quadpill group
.... 14.757 randomized into groups for PARACHUTE Trial
.... 14.758 Rate of Adverse Events of Special Interest (NCT03640312)
.... 14.759 Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312
.... 14.760 Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312
.... 14.761 Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312
.... 14.762 Rate of Death or Major Traumatic Injury on Impact with comparator
.... 14.763 Rate of Death or Major Traumatic Injury on Impact with intervention
.... 14.764 Reasons for exclusion from QUARTET USA Trial
.... 14.765 Recommendation Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17)
.... 14.766 Recommendation Justification Code System
.... 14.767 Recommendation Rating: ADA Obesity Management Recommendation 8.16
.... 14.768 Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.769 Recommendation: ADA Obesity Management Recommendation 8.16-adapted
.... 14.770 Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.771 RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16)
.... 14.772 Remdesivir
.... 14.773 Remdesivir IV 200 mg once then 100 mg once daily for 9 days
.... 14.774 ResearchStudy Classifier Code System
.... 14.775 Results Section for NCT03421379
.... 14.776 Results Section for NCT03640312
.... 14.777 Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.778 Risk of Bias Assessment of PARACHUTE trial
.... 14.779 Risk Of Bias Type Value Set
.... 14.780 Screened Group PARACHUTE Trial
.... 14.781 Search Strategy for NMA_Diabetes
.... 14.782 SearchResults: PubMed search for Wonder Woman
.... 14.783 SearchStrategy: PubMed and Embase search for van Veldhuisen 2022 systematic review
.... 14.784 SearchStrategy: PubMed search for Wonder Woman
.... 14.785 Sex
.... 14.786 Sex with comparator
.... 14.787 Sex with intervention
.... 14.788 SGLT2 inhibitors Group in Adults with type 2 diabetes
.... 14.789 SoaPlanDefinition: Follow-up assessment 3 months after study start
.... 14.790 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
.... 14.791 Spanish or English Value Set
.... 14.792 Standard care Group in Adults with type 2 diabetes with moderate CV risk
.... 14.793 StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488
.... 14.794 StudyEligibilityCriteria: Eligibility Criteria for DIBASY Trial
.... 14.795 StudyEligibilityCriteria: Obese patients ≥ 18 years old
.... 14.796 StudyEligibilityCriteria: Type 2 diabetes and elevated BMI in 2016 meta-analysis
.... 14.797 StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study
.... 14.798 StudyGroup: Diabetes Surgery Study Trial Enrollment Group
.... 14.799 StudyGroup: Severely Obese Adults 2018 Norwegian Cohort
.... 14.800 StudyGroup_DIBASY_Trial_Enrollment_Group
.... 14.801 Summary of Findings - QUARTET USA Trial
.... 14.802 SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 14.803 SummaryOfFindings: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
.... 14.804 SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.805 SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 14.806 SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.807 SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.808 SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.809 Systolic blood pressure at 12 weeks
.... 14.810 Time to integration of results in a recommendation
.... 14.811 VariableDefinition: Comparator
.... 14.812 VariableDefinition: Condition(s)
.... 14.813 VariableDefinition: Date of birth
.... 14.814 VariableDefinition: Date of measurement
.... 14.815 VariableDefinition: Gender
.... 14.816 VariableDefinition: NTproBNP
.... 14.817 VariableDefinition: Unit
.... 14.818 Velocity
.... 14.819 Velocity comparing intervention vs. comparator
.... 14.820 Velocity for enrolled group
.... 14.821 Velocity for non participant group
.... 14.822 Velocity with comparator
.... 14.823 Velocity with intervention
.... 14.824 WebPageCitation: A HEvKA Update Summary
.... 14.825 Weight
.... 14.826 Weight with comparator
.... 14.827 Weight with intervention